华润双鹤药业股份有限公司 关于控股子公司双鹤天安药业(贵州)股份有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公 司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到贵 州省药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号： 黔 20250059)，现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：双鹤天安药业(贵州)股份有限公司 检查地址：贵州省贵阳市乌当区高新路 25 号 检查范围及相关车间、生产线： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－096 片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍 500mg 与恩 格列净 5mg)，综合车间(四)片剂生产线，自行生产] 检查时间：2025 年 10 月 15 日至 10 月 17 日 结论：符合 本次检查是二甲双胍恩格列净片(Ⅰ)上市前的首次药品 GMP 符合 性检查。上述检查项目是在原有厂房、设备情况下的检 ...

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its subsidiary, Double Crane Tianan Pharmaceutical (贵州双鹤天安药业), received a GMP compliance inspection notice from the Guizhou Provincial Drug Administration, indicating regulatory approval for its production line [1] Group 1: Company Information - The subsidiary involved is Double Crane Tianan Pharmaceutical, which is located in Guizhou [1] - The production line is designed for the manufacturing of Metformin and Ertugliflozin tablets, with a capacity of 500 million tablets per year [1] Group 2: Regulatory Approval - The notice received is titled "Drug GMP Compliance Inspection Notice" with the reference number: 黔20250059 [1] - The inspection covered the tablet production line and related workshops, confirming compliance with GMP standards [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its subsidiary, Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd., received a GMP compliance inspection notice from the Guizhou Provincial Drug Administration [1] Group 1: Company Developments - The inspection notice (No. 黔20250059) pertains to the production of Metformin and Ertugliflozin tablets (Ⅰ), with each tablet containing 500mg of Metformin Hydrochloride and 5mg of Ertugliflozin [1] - The production line involved in the inspection is designed with an annual capacity of 500 million tablets [1]

华润双鹤公告，控股子公司双鹤天安药业(贵州)股份有限公司收到贵州省药品监督管理局颁发的《药品 GMP符合性检查告知书》。检查范围为片剂，检查时间为2025年10月15日至10月17日，结论为符合。 ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

Core Viewpoint - The article discusses the establishment of significant investment funds by China Resources Double Crane and China Resources Pharmaceutical, focusing on synthetic biology and innovative pharmaceuticals, indicating a strategic shift towards high-growth sectors in the biomanufacturing industry [2][3]. Investment Fund Establishment - China Resources Double Crane and China Resources Pharmaceutical announced the formation of a 500 million RMB fund, with a commitment of 123 million RMB from the group, representing 24.6% of the total fund [2]. - China Resources Double Crane also established the "China Resources Double Crane Industry Fund," committing up to 83 million RMB, approximately 16.6% of the total fund, aimed at optimizing strategic layout in synthetic biology [3]. Collaboration and Partnerships - The funds involve collaboration with local governments and multiple investors, including 11 limited partners (LPs) such as various China Resources entities and Chengdu local government funds, collectively forming a 1 billion RMB investment fund [3][4]. - The partnership includes significant contributions from local government funds and private enterprises, showcasing a collaborative approach to investment in the biomanufacturing sector [4]. Strategic Focus on Synthetic Biology - China Resources Double Crane has previously invested 502 million RMB to acquire a 50.11% stake in Shenzhou Biology, enhancing its capabilities in the biomanufacturing field [5]. - The establishment of a synthetic biology research institute in 2023 indicates a commitment to developing a comprehensive R&D, pilot testing, and industrialization system, focusing on industrial enzymes and microorganisms [5]. Research and Development Initiatives - The company has developed seven technology platforms in synthetic biology, with over ten ongoing projects, leveraging expertise from seasoned scientists with experience in major corporations [5].

Core Viewpoint - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony highlighted the achievements of companies in the capital market, with Huaren Shuanghe's chairman receiving the "Golden Bull Entrepreneur Innovation Award" for his contributions to innovation and value creation [1][2]. Group 1: Event Overview - The Golden Bull Award, established in 1999, aims to create a credible platform for showcasing listed companies in China's capital market, emphasizing transparency and scientific evaluation [1]. - The award recognizes companies with exemplary governance, performance growth, and positive contributions to shareholders and society [1]. Group 2: Company Innovations and Achievements - During the "14th Five-Year Plan" period, the company adopted a dual-driven approach of "R&D innovation + external development," focusing on developing high-quality drugs that meet clinical needs [2]. - The successful introduction of the innovative drug "Subi One" exemplifies the company's commitment to clinical value and innovation [2]. - The company aims to establish itself as "China's prescription drug number one brand" and is determined to represent state-owned enterprises in innovation and transformation [2]. - In the latest 2025 ranking of China's top 100 chemical drug companies, Huaren Shuanghe advanced to the 13th position, showcasing its competitive edge in a crowded market [2].

Core Viewpoint - China Resources Double Crane is a leading chemical formulation production enterprise in China, focusing on drug development, manufacturing, and sales, with a differentiated advantage across the entire industry chain [1] Group 1: Business Performance - In Q3 2025, China Resources Double Crane reported revenue of 8.283 billion yuan, ranking 10th in the industry, significantly above the industry average of 2.8 billion yuan and median of 838 million yuan, but still trailing behind the top competitors [2] - The net profit for the same period was 1.388 billion yuan, ranking 8th in the industry, well above the industry average of 299 million yuan and median of 78.29 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 28.52%, down from 34.19% year-on-year and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 59.31%, an increase from 58.46% year-on-year and above the industry average of 57.17%, reflecting robust profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.51% to 57,700, with an average holding of 17,900 circulating A-shares, a decrease of 0.51% [5] - Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 9.2933 million shares, down by 2.9481 million shares from the previous period [5] Group 4: Executive Compensation - The chairman, Lu Wenchao, received a salary of 2.7006 million yuan in 2024, an increase of 381,100 yuan from 2023 [4] - The president, Zhao Qian, earned 150,300 yuan in 2024 [4] Group 5: Research Insights - Huatai Securities noted that the company achieved revenue of 8.28 billion yuan and net profit of 1.35 billion yuan in the first three quarters of 2025, with positive profit growth in Q3 [6] - Key business highlights include stable revenue in the non-infusion segment and growth in the specialty segment, while the infusion segment is expected to maintain net profit through packaging upgrades [6] - CICC maintained profit forecasts of 1.742 billion yuan and 1.864 billion yuan for 2025 and 2026, respectively, with a target price of 25 yuan [6]

Core Viewpoint - China Resources Pharmaceutical announced the establishment of a 500 million yuan fund focused on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane (600062) and China Resources Pharmaceutical Investment as limited partners [1] - China Resources Pharmaceutical Group plans to invest 123 million yuan, accounting for approximately 24.6% of the total fund size [1] - Shenzhen China Resources Capital will act as the fund manager [1] Group 2: Strategic Goals - The establishment of the fund aligns with the group's strategic direction in synthetic biology, aiming to build an industrialization platform in Hohhot [1] - The fund is expected to enhance investment channels, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - Once established, the fund will be recorded as equity investment in the company's consolidated financial statements [1]